Bruker (NASDAQ:BRKR)‘s stock had its “hold” rating reiterated by analysts at Barclays in a report issued on Monday, AnalystRatings.com reports. They currently have a $44.00 price objective on the medical research company’s stock. Barclays‘s price objective suggests a potential downside of 9.02% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the company. Jefferies Financial Group upped their price target on Bruker from $45.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, June 21st. BTIG Research upped their price target on Bruker to $57.00 and gave the stock a “buy” rating in a report on Friday, June 21st. BidaskClub upgraded Bruker from a “hold” rating to a “buy” rating in a report on Wednesday, June 5th. Deutsche Bank upgraded Bruker from a “hold” rating to a “buy” rating and upped their price target for the stock from $40.00 to $50.00 in a report on Friday, April 12th. Finally, Zacks Investment Research cut Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $48.20.
BRKR opened at $48.36 on Monday. The firm has a market cap of $7.65 billion, a PE ratio of 34.54, a P/E/G ratio of 2.46 and a beta of 1.25. The company has a current ratio of 2.12, a quick ratio of 1.27 and a debt-to-equity ratio of 0.42. The stock has a 50 day moving average price of $43.80. Bruker has a 1-year low of $26.10 and a 1-year high of $49.88.
In other Bruker news, Director Marc A. Kastner sold 1,374 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $41.79, for a total transaction of $57,419.46. Following the sale, the director now owns 10,811 shares in the company, valued at approximately $451,791.69. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Frank H. Laukien sold 400,000 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $41.48, for a total value of $16,592,000.00. Following the sale, the chief executive officer now owns 37,991,030 shares in the company, valued at approximately $1,575,867,924.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 801,374 shares of company stock worth $33,241,419. 26.50% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in BRKR. JPMorgan Chase & Co. grew its position in Bruker by 33.4% during the third quarter. JPMorgan Chase & Co. now owns 96,033 shares of the medical research company’s stock valued at $3,213,000 after acquiring an additional 24,048 shares during the last quarter. Rhumbline Advisers grew its position in Bruker by 3.3% during the fourth quarter. Rhumbline Advisers now owns 102,048 shares of the medical research company’s stock valued at $3,038,000 after acquiring an additional 3,254 shares during the last quarter. SG Americas Securities LLC bought a new position in Bruker during the fourth quarter valued at approximately $176,000. Canada Pension Plan Investment Board bought a new position in Bruker during the fourth quarter valued at approximately $6,451,000. Finally, Comerica Bank bought a new position in Bruker during the fourth quarter valued at approximately $219,000. Hedge funds and other institutional investors own 66.73% of the company’s stock.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
See Also: Analyst Ratings Trading
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.